|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MLST8 |
Gene summary for MLST8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MLST8 | Gene ID | 64223 |
| Gene name | MTOR associated protein, LST8 homolog | |
| Gene Alias | GBL | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q9BVC4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64223 | MLST8 | LZE4T | Human | Esophagus | ESCC | 2.37e-06 | 1.68e-01 | 0.0811 |
| 64223 | MLST8 | LZE7T | Human | Esophagus | ESCC | 3.10e-07 | 4.08e-01 | 0.0667 |
| 64223 | MLST8 | LZE8T | Human | Esophagus | ESCC | 2.15e-14 | 2.34e-01 | 0.067 |
| 64223 | MLST8 | LZE20T | Human | Esophagus | ESCC | 1.16e-08 | 2.59e-01 | 0.0662 |
| 64223 | MLST8 | LZE22T | Human | Esophagus | ESCC | 4.40e-06 | 4.79e-01 | 0.068 |
| 64223 | MLST8 | LZE24T | Human | Esophagus | ESCC | 9.57e-15 | 3.78e-01 | 0.0596 |
| 64223 | MLST8 | LZE21T | Human | Esophagus | ESCC | 2.25e-05 | 2.39e-01 | 0.0655 |
| 64223 | MLST8 | LZE6T | Human | Esophagus | ESCC | 3.92e-03 | 1.52e-01 | 0.0845 |
| 64223 | MLST8 | P1T-E | Human | Esophagus | ESCC | 1.87e-17 | 5.73e-01 | 0.0875 |
| 64223 | MLST8 | P2T-E | Human | Esophagus | ESCC | 6.02e-67 | 1.20e+00 | 0.1177 |
| 64223 | MLST8 | P4T-E | Human | Esophagus | ESCC | 2.32e-51 | 1.16e+00 | 0.1323 |
| 64223 | MLST8 | P5T-E | Human | Esophagus | ESCC | 4.80e-25 | 4.72e-01 | 0.1327 |
| 64223 | MLST8 | P8T-E | Human | Esophagus | ESCC | 1.62e-28 | 5.13e-01 | 0.0889 |
| 64223 | MLST8 | P9T-E | Human | Esophagus | ESCC | 1.70e-16 | 2.90e-01 | 0.1131 |
| 64223 | MLST8 | P10T-E | Human | Esophagus | ESCC | 9.54e-33 | 5.09e-01 | 0.116 |
| 64223 | MLST8 | P11T-E | Human | Esophagus | ESCC | 7.46e-16 | 6.43e-01 | 0.1426 |
| 64223 | MLST8 | P12T-E | Human | Esophagus | ESCC | 5.38e-43 | 9.07e-01 | 0.1122 |
| 64223 | MLST8 | P15T-E | Human | Esophagus | ESCC | 7.32e-29 | 6.03e-01 | 0.1149 |
| 64223 | MLST8 | P16T-E | Human | Esophagus | ESCC | 3.26e-26 | 4.97e-01 | 0.1153 |
| 64223 | MLST8 | P17T-E | Human | Esophagus | ESCC | 9.88e-20 | 6.98e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000806418 | Oral cavity | LP | regulation of actin polymerization or depolymerization | 69/4623 | 188/18723 | 1.55e-04 | 1.76e-03 | 69 |
| GO:007190015 | Oral cavity | LP | regulation of protein serine/threonine kinase activity | 119/4623 | 359/18723 | 1.70e-04 | 1.90e-03 | 119 |
| GO:003083217 | Oral cavity | LP | regulation of actin filament length | 69/4623 | 189/18723 | 1.86e-04 | 2.05e-03 | 69 |
| GO:003004119 | Oral cavity | LP | actin filament polymerization | 69/4623 | 191/18723 | 2.65e-04 | 2.75e-03 | 69 |
| GO:000815419 | Oral cavity | LP | actin polymerization or depolymerization | 76/4623 | 218/18723 | 4.67e-04 | 4.42e-03 | 76 |
| GO:0110053110 | Oral cavity | LP | regulation of actin filament organization | 92/4623 | 278/18723 | 9.25e-04 | 7.85e-03 | 92 |
| GO:004325429 | Skin | cSCC | regulation of protein-containing complex assembly | 167/4864 | 428/18723 | 1.60e-09 | 5.97e-08 | 167 |
| GO:190290329 | Skin | cSCC | regulation of supramolecular fiber organization | 145/4864 | 383/18723 | 1.67e-07 | 3.71e-06 | 145 |
| GO:0031334112 | Skin | cSCC | positive regulation of protein-containing complex assembly | 97/4864 | 237/18723 | 3.22e-07 | 6.51e-06 | 97 |
| GO:0051258112 | Skin | cSCC | protein polymerization | 114/4864 | 297/18723 | 1.55e-06 | 2.62e-05 | 114 |
| GO:000701529 | Skin | cSCC | actin filament organization | 156/4864 | 442/18723 | 7.37e-06 | 1.02e-04 | 156 |
| GO:003297029 | Skin | cSCC | regulation of actin filament-based process | 142/4864 | 397/18723 | 8.50e-06 | 1.13e-04 | 142 |
| GO:1902905112 | Skin | cSCC | positive regulation of supramolecular fiber organization | 83/4864 | 209/18723 | 8.87e-06 | 1.17e-04 | 83 |
| GO:0032271112 | Skin | cSCC | regulation of protein polymerization | 89/4864 | 233/18723 | 2.57e-05 | 2.91e-04 | 89 |
| GO:0110053111 | Skin | cSCC | regulation of actin filament organization | 103/4864 | 278/18723 | 2.78e-05 | 3.12e-04 | 103 |
| GO:003295629 | Skin | cSCC | regulation of actin cytoskeleton organization | 127/4864 | 358/18723 | 3.83e-05 | 4.13e-04 | 127 |
| GO:0051495110 | Skin | cSCC | positive regulation of cytoskeleton organization | 86/4864 | 226/18723 | 4.08e-05 | 4.34e-04 | 86 |
| GO:0032273112 | Skin | cSCC | positive regulation of protein polymerization | 57/4864 | 138/18723 | 5.96e-05 | 5.86e-04 | 57 |
| GO:0008154110 | Skin | cSCC | actin polymerization or depolymerization | 81/4864 | 218/18723 | 1.70e-04 | 1.47e-03 | 81 |
| GO:0032535111 | Skin | cSCC | regulation of cellular component size | 131/4864 | 383/18723 | 1.89e-04 | 1.59e-03 | 131 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04714211 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
| hsa0414010 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa041362 | Esophagus | ESCC | Autophagy - other | 23/4205 | 32/8465 | 8.99e-03 | 2.14e-02 | 1.09e-02 | 23 |
| hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa04714310 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
| hsa0414015 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa0413611 | Esophagus | ESCC | Autophagy - other | 23/4205 | 32/8465 | 8.99e-03 | 2.14e-02 | 1.09e-02 | 23 |
| hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0471414 | Liver | Cirrhotic | Thermogenesis | 121/2530 | 232/8465 | 5.70e-13 | 1.36e-11 | 8.36e-12 | 121 |
| hsa041406 | Liver | Cirrhotic | Autophagy - animal | 65/2530 | 141/8465 | 3.10e-05 | 2.47e-04 | 1.52e-04 | 65 |
| hsa0471415 | Liver | Cirrhotic | Thermogenesis | 121/2530 | 232/8465 | 5.70e-13 | 1.36e-11 | 8.36e-12 | 121 |
| hsa0414011 | Liver | Cirrhotic | Autophagy - animal | 65/2530 | 141/8465 | 3.10e-05 | 2.47e-04 | 1.52e-04 | 65 |
| hsa0471422 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
| hsa0414021 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
| hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa0471432 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
| hsa0414031 | Liver | HCC | Autophagy - animal | 99/4020 | 141/8465 | 3.08e-08 | 4.70e-07 | 2.61e-07 | 99 |
| hsa0415011 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MLST8 | SNV | Missense_Mutation | novel | c.706N>A | p.Ala236Thr | p.A236T | Q9BVC4 | protein_coding | deleterious(0.02) | probably_damaging(0.968) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MLST8 | insertion | Frame_Shift_Ins | novel | c.421_422insGCTGCATCTGTTACCGCCCTGAGGAGCAC | p.Ala141GlyfsTer27 | p.A141Gfs*27 | Q9BVC4 | protein_coding | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | ||
| MLST8 | SNV | Missense_Mutation | c.161N>A | p.Arg54His | p.R54H | Q9BVC4 | protein_coding | deleterious(0) | possibly_damaging(0.772) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MLST8 | SNV | Missense_Mutation | c.258N>T | p.Lys86Asn | p.K86N | Q9BVC4 | protein_coding | tolerated(0.22) | possibly_damaging(0.772) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MLST8 | SNV | Missense_Mutation | novel | c.556N>A | p.Ala186Thr | p.A186T | Q9BVC4 | protein_coding | deleterious(0.01) | possibly_damaging(0.625) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MLST8 | SNV | Missense_Mutation | novel | c.46N>A | p.Ala16Thr | p.A16T | Q9BVC4 | protein_coding | deleterious(0.01) | probably_damaging(0.946) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| MLST8 | SNV | Missense_Mutation | c.258G>T | p.Lys86Asn | p.K86N | Q9BVC4 | protein_coding | tolerated(0.22) | possibly_damaging(0.772) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MLST8 | SNV | Missense_Mutation | novel | c.691G>A | p.Asp231Asn | p.D231N | Q9BVC4 | protein_coding | deleterious(0.02) | possibly_damaging(0.895) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MLST8 | SNV | Missense_Mutation | rs774913271 | c.661N>T | p.Arg221Cys | p.R221C | Q9BVC4 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MLST8 | SNV | Missense_Mutation | c.743G>T | p.Arg248Met | p.R248M | Q9BVC4 | protein_coding | deleterious(0.01) | possibly_damaging(0.905) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 64223 | MLST8 | KINASE | inhibitor | AZD8055 | AZD-8055 | |
| 64223 | MLST8 | KINASE | inhibitor | MLN0128 | SAPANISERTIB | |
| 64223 | MLST8 | KINASE | inhibitor | OSI-027 | OSI-027 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |